The emergence of multidrug-resistant Pseudomonas aeruginosa possesses a significant public health concern. Constitutively expressed MexAB–OprM efflux pumps in P. aeruginosa significantly contribute to its resistance to a variety of antibiotics. The development of efflux pump inhibitors (EPIs) has emerged as an attractive strategy in reversing antibiotic resistance. In this study, structure-based virtual screening techniques were used for the identification of new MexAB–OprM efflux inhibitors. The predicted poses were thoroughly filtered by induced fit docking procedures followed by in vitro microbiological assays for the validation of in silico results. Two compounds, NSC-147850 and NSC-112703, were able to restore tetracycline susceptibility in MexAB–OprM overexpressing Pseudomonas aeruginosa ATCC® 27853™ strain. This correlation observed between in silico screening and positive efflux inhibitory activity in vitro suggests that NSC-147850 and NSC-112703 have potential as EPIs and may be effective in combination therapy against drug-resistant strains of P. aeruginosa.
Get full access to this article
View all access options for this article.
References
1.
Talebi Bezmin AbadiA, RizvanovAA, HaertléT, et al.World Health Organization Report: Current crisis of antibiotic resistance. BioNanoScience, 2019; 9(4):778–788.
LitwinA, RojekS, GozdzikW, et al.Pseudomonas aeruginosa device associated—Healthcare associated infections and its multidrug resistance at intensive care unit of University Hospital: Polish, 8.5-year, prospective, single-centre study. BMC Infect Dis, 2021; 21:180.
7.
QinS, XiaoW, ZhouC, et al.Pseudomonas aeruginosa: Pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. Signal Transduct Target Ther, 2022; 7:199.
8.
De KievitTR, ParkinsMD, GillisRJ, et al.Multidrug efflux pumps: Expression patterns and contribution to antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother, 2001; 45(6):1761–1770.
9.
AkamaH, MatsuuraT, KashiwagiS, et al.Crystal structure of the membrane fusion protein, MexA, of the multidrug transporter in Pseudomonas aeruginosa. J Biol Chem, 2004; 279(25):25939–25942.
10.
SennhauserG, BukowskaMA, BriandC, et al.Crystal structure of the multidrug exporter MexB from Pseudomonas aeruginosa. J Mol Biol, 2009; 389(1):134–145.
11.
PhanG, BenabdelhakH, LascombeMB, et al.Structural and dynamical insights into the opening mechanism of P. aeruginosa OprM channel. Struct Lond Engl 1993, 2010; 18(4):507–517.
12.
TsutsumiK, YoneharaR, Ishizaka-IkedaE, et al.Structures of the wild-type MexAB-OprM tripartite pump reveal its complex formation and drug efflux mechanism. Nat Commun, 2019; 10(1):1520.
13.
TikhonovaEB, WangQ, ZgurskayaHI. Chimeric analysis of the multicomponent multidrug efflux transporters from Gram-Negative Bacteria. J Bacteriol, 2002; 184(23):6499–6507.
14.
WangB, WengJ, WangW. Substrate binding accelerates the conformational transitions and substrate dissociation in multidrug efflux transporter AcrB. Front Microbiol, 2015; 6:302.
15.
NakashimaR, SakuraiK, YamasakiS, et al.Structures of the multidrug exporter AcrB reveal a proximal multisite drug-binding pocket. Nature, 2011; 480(7378):565–569.
16.
RamaswamyVK, VargiuAV, MallociG, et al.Molecular determinants of the promiscuity of MexB and MexY multidrug transporters of Pseudomonas aeruginosa. Front Microbiol, 2018; 9:1144.
17.
SharmaA, GuptaVK, PathaniaR. Efflux pump inhibitors for bacterial pathogens: From bench to bedside. Indian J Med Res, 2019; 149(2):129–145.
18.
LomovskayaO, WarrenMS, LeeA, et al.Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: Novel agents for combination therapy. Antimicrob Agents Chemother, 2001; 45(1):105–116.
19.
SjutsH, VargiuAV, KwasnySM, et al.Molecular basis for inhibition of AcrB multidrug efflux pump by novel and powerful pyranopyridine derivatives. Proc Natl Acad Sci USA, 2016; 113(13):3509–3514.
20.
NakashimaR, SakuraiK, YamasakiS, et al.Structural basis for the inhibition of bacterial multidrug exporters. Nature, 2013; 500(7460):102–106.
21.
Schrödinger. Schrödinger Release 2017-3 Maest Schrödinger LLC N Y NY. 2017.
22.
Madhavi SastryG, AdzhigireyM, DayT, et al.Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des, 2013; 27(3):221–234.
23.
Halgren TA. Identifying and characterizing binding sites and assessing druggability. J Chem Inf Model, 2009; 49(2):377–389.
24.
de RuyckJ, BrysbaertG, BlosseyR, et al.Molecular docking as a popular tool in drug design, an in silico travel. Adv Appl Bioinforma Chem AABC, 2016; 9:1–11.
25.
ShermanW, DayT, JacobsonMP, et al.Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem, 2006; 49(2):534–553.
26.
JacobsonMP, PincusDL, RappCS, et al.A hierarchical approach to all-atom protein loop prediction. Proteins, 2004; 55(2):351–367.
27.
Clinical and Laboratory Standards Institute. M100-S25: Performance Standards for Antimicrobial Susceptibility Testing. CLSI: Wayne, PA, USA; 2015.
28.
JeongSH, SongW, BaeIK, et al.Broth microdilution methods using B-lactamase inhibitors for the identification of Klebsiella pneumoniae carbapenemases and metallo-β-lactamases in Gram-negative bacilli. Ann Clin Lab Sci, 2014; 44(1):49–55.
29.
Osei SekyereJ, AmoakoDG. Carbonyl Cyanide m-Chlorophenylhydrazine (CCCP) reverses resistance to colistin, but not to carbapenems and tigecycline in multidrug-resistant Enterobacteriaceae. Front Microbiol, 2017; 8:228.
30.
BohnertJA, KernWV. Selected arylpiperazines are capable of reversing multidrug resistance in Escherichia coli overexpressing RND efflux pumps. Antimicrob Agents Chemother, 2005; 49(2):849–852.
31.
GreenAT, MoniruzzamanM, CooperCJ, et al.Discovery of multidrug efflux pump inhibitors with a novel chemical scaffold. Biochim Biophys Acta Gen Subj, 2020; 1864(6):129546.
32.
NguyenST, KwasnySM, DingX, et al.Structure-activity relationships of a novel pyranopyridine series of Gram-negative bacterial efflux pump inhibitors. Bioorg Med Chem, 2015; 23(9):2024–2034.
CoelhoT, MachadoD, CoutoI, et al.Enhancement of antibiotic activity by efflux inhibitors against multidrug resistant Mycobacterium tuberculosis clinical isolates from Brazil. Front Microbiol, 2015; 6:330.
35.
CatalanoA, IacopettaD, CeramellaJ, et al.Multidrug resistance (MDR): A widespread phenomenon in pharmacological therapies. Molecules, 2022; 27(3):616.
36.
KishkRM, AbdallaMO, HashishAA, et al.Efflux MexAB-mediated resistance in P. aeruginosa isolated from patients with healthcare associated infections. Pathogens, 2020; 9(6):471.
37.
HalgrenTA, MurphyRB, FriesnerRA, et al.Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment Factors in Database Screening. J Med Chem, 2004; 47(7):1750–1759.
38.
Abdel-HalimH, Al DajaniA, AbdelhalimA, et al.The search of potential inhibitors of the AcrAB-TolC system of multidrug-resistant Escherichia coli: an in silico approach. Appl Microbiol Biotechnol, 2019; 103(15):6309–6318.
39.
YeZ, BaumgartnerMP, WingertBM, et al.Optimal strategies for virtual screening of induced-fit and flexible target in the 2015 D3R Grand Challenge. J Comput Aided Mol Des, 2016; 30(9):695–706.
40.
ArabestaniMR, RajabpourM, Yousefi MashoufR, et al.Expression of efflux pump MexAB-OprM and OprD of Pseudomonas aeruginosa strains isolated from clinical samples using qRT-PCR. Arch Iran Med, 2015; 18(2):102–108.
41.
GoliHR, NahaeiMR, RezaeeMA, et al.Role of MexAB-OprM and MexXY-OprM efflux pumps and class 1 integrons in resistance to antibiotics in burn and Intensive Care Unit isolates of Pseudomonas aeruginosa. J Infect Public Health, 2018; 11(3):364–372.
42.
IkonomidisA, TsakrisA, KanellopoulouM, et al.Effect of the proton motive force inhibitor carbonyl cyanide-m-chlorophenylhydrazone (CCCP) on Pseudomonas aeruginosa biofilm development. Lett Appl Microbiol, 2008; 47(4):298–302.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
